28501028|t|Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report
28501028|a|Castleman disease is a rare lymphoproliferative disorder presenting with localized or disseminated lymphadenopathy and systemic manifestations. It can be categorized in numerous ways, such as unicentric versus multicentric, histopathological variants (hyaline - vascular, plasma cell, and mixed), or subtypes based on causative viral infections (human immunodeficiency virus, human herpesvirus-8, or Kaposi sarcoma herpesvirus). Presentation ranges from asymptomatic to symptoms involving multiple organs. Even though the exact mechanism of pathogenesis is unknown, treatment is directed toward possible etiologies such as interleukin-6, cluster of differentiation 20, and viral agents. A 36- year -old Sri Lankan woman presented with generalized body swelling and foamy urine of 2 weeks ' duration. Examination revealed pallor; generalized edema; axillary, cervical, and inguinal lymphadenopathy; hypertension; and hepatomegaly. Investigations showed bicytopenia, nephrotic range proteinuria with hypoalbuminemia, hypogammaglobulinemia, and features of hyaline - vascular type Castleman disease in a lymph node biopsy. She was managed with rituximab and had good clinical improvement. Castleman disease has a broad spectrum of clinical manifestations, disease pathogeneses, and associations and/or complications. Medical professionals need to be familiar with this spectrum because timely diagnosis and aggressive targeted therapy are the cornerstones of managing these patients.
28501028	0	30	Multicentric Castleman disease	T191	C1334815
28501028	34	41	hyaline	T031	C0020191
28501028	42	50	vascular	T023	C0005847
28501028	51	58	variant	T080	C0205419
28501028	75	82	unusual	T080	C2700116
28501028	83	91	systemic	T169	C0205373
28501028	92	106	manifestations	T080	C1280464
28501028	110	121	case report	T170	C0007320
28501028	122	139	Castleman disease	T191	C1334815
28501028	145	149	rare	T080	C0522498
28501028	150	178	lymphoproliferative disorder	T191	C0024314
28501028	195	204	localized	T082	C0392752
28501028	208	220	disseminated	T082	C0205221
28501028	221	236	lymphadenopathy	T047	C0497156
28501028	241	249	systemic	T169	C0205373
28501028	250	264	manifestations	T080	C1280464
28501028	276	287	categorized	T185	C0008902
28501028	291	299	numerous	T081	C0439064
28501028	314	324	unicentric	T047	C0017531
28501028	332	344	multicentric	T191	C1334815
28501028	346	363	histopathological	T169	C0243140
28501028	364	372	variants	T080	C0205419
28501028	374	381	hyaline	T031	C0020191
28501028	384	392	vascular	T023	C0005847
28501028	394	405	plasma cell	T025	C0032112
28501028	411	416	mixed	T080	C0205419
28501028	422	430	subtypes	T185	C0872379
28501028	440	449	causative	T033	C0449411
28501028	450	466	viral infections	T047	C0042769
28501028	468	496	human immunodeficiency virus	T005	C0019682
28501028	498	517	human herpesvirus-8	T005	C0376526
28501028	522	548	Kaposi sarcoma herpesvirus	T005	C0376526
28501028	576	588	asymptomatic	T033	C0231221
28501028	592	600	symptoms	T184	C1457887
28501028	611	619	multiple	T081	C0439064
28501028	620	626	organs	T023	C0178784
28501028	650	659	mechanism	T169	C0441712
28501028	663	675	pathogenesis	T046	C0699748
28501028	688	697	treatment	T169	C1522326
28501028	701	709	directed	T080	C1879741
28501028	726	736	etiologies	T169	C0015127
28501028	745	758	interleukin-6	T116,T129	C0021760
28501028	760	789	cluster of differentiation 20	T116,T129	C0054946
28501028	795	807	viral agents	T169	C0521026
28501028	815	819	year	T079	C0439234
28501028	825	835	Sri Lankan	T098	C1553327
28501028	836	841	woman	T098	C0043210
28501028	869	882	body swelling	T184	C0577596
28501028	887	898	foamy urine	T184	C2188715
28501028	904	909	weeks	T079	C0439230
28501028	912	920	duration	T079	C0449238
28501028	922	933	Examination	T058	C0582103
28501028	943	949	pallor	T033	C0030232
28501028	951	968	generalized edema	T033	C1850534
28501028	970	978	axillary	T029	C0004454
28501028	980	988	cervical	T082	C0205064
28501028	994	1018	inguinal lymphadenopathy	T047	C0578736
28501028	1020	1032	hypertension	T047	C0020538
28501028	1038	1050	hepatomegaly	T033	C0019209
28501028	1052	1066	Investigations	T058	C1261322
28501028	1074	1085	bicytopenia	T034	C1142446
28501028	1087	1114	nephrotic range proteinuria	T033	C0445118
28501028	1120	1135	hypoalbuminemia	T047	C0239981
28501028	1137	1158	hypogammaglobulinemia	T047	C0086438
28501028	1164	1172	features	T080	C2348519
28501028	1176	1183	hyaline	T031	C0020191
28501028	1186	1194	vascular	T023	C0005847
28501028	1195	1199	type	T080	C0332307
28501028	1200	1217	Castleman disease	T191	C1334815
28501028	1223	1240	lymph node biopsy	T060	C0193842
28501028	1250	1257	managed	T058	C0086583
28501028	1263	1272	rituximab	T116,T121,T129	C0393022
28501028	1286	1294	clinical	T080	C0205210
28501028	1295	1306	improvement	T077	C2986411
28501028	1308	1325	Castleman disease	T191	C1334815
28501028	1332	1337	broad	T082	C0332464
28501028	1338	1346	spectrum	T077	C2827424
28501028	1350	1358	clinical	T080	C0205210
28501028	1359	1373	manifestations	T080	C1280464
28501028	1375	1382	disease	T047	C0012634
28501028	1383	1395	pathogeneses	T046	C0699748
28501028	1401	1413	associations	T080	C0205556
28501028	1421	1434	complications	T046	C0009566
28501028	1436	1443	Medical	T169	C0205476
28501028	1444	1457	professionals	T097	C1704312
28501028	1488	1496	spectrum	T077	C2827424
28501028	1512	1521	diagnosis	T033	C0011900
28501028	1526	1553	aggressive targeted therapy	T061	C2985566
28501028	1593	1601	patients	T101	C0030705